Literature DB >> 21209124

Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial.

Frederike G I van Vilsteren1, Roos E Pouw, Stefan Seewald, Lorenza Alvarez Herrero, Carine M T Sondermeijer, Mike Visser, Fiebo J W Ten Kate, Karl C Yu Kim Teng, Nib Soehendra, Thomas Rösch, Bas L A M Weusten, Jacques J G H M Bergman.   

Abstract

OBJECTIVE: After focal endoscopic resection (ER) of high-grade dysplasia (HGD) or early cancer (EC) in Barrett's oesophagus (BO), eradication of all remaining BO reduces the recurrence risk. The aim of this study was to compare the safety of stepwise radical ER (SRER) versus focal ER followed by radiofrequency ablation (RFA) for complete eradication of BO containing HGD/EC.
METHODS: A multicentre randomised clinical trial was carried out in three tertiary centres. Patients with BO ≤ 5 cm containing HGD/EC were randomised to SRER or ER/RFA. Patients in the SRER group underwent piecemeal ER of 50% of BO followed by serial ER. Patients in the ER/RFA group underwent focal ER for visible lesions followed by serial RFA. Follow-up endoscopy with biopsies (four-quadrant/2 cm BO) was performed at 6 and 12 months and then annually. The main outcome measures were: stenosis rate; complications; complete histological response for neoplasia (CR-neoplasia); and complete histological response for intestinal metaplasia (CR-IM).
RESULTS: CR-neoplasia was achieved in 25/25 (100%) SRER and in 21/22 (96%) ER/RFA patients. CR-IM was achieved in 23 (92%) SRER and 21 (96%) ER/RFA patients. The stenosis rate was significantly higher in SRER (88%) versus ER/RFA (14%; p<0.001), resulting in more therapeutic sessions in SRER (6 vs 3; p<0.001) due to dilations. After median 24 months follow-up, one SRER patient had recurrence of EC, requiring ER.
CONCLUSIONS: In patients with BO ≤ 5 cm containing HGD/EC, SRER and ER/RFA achieved comparably high rates of CR-IM and CR-neoplasia. However, SRER was associated with a higher number of complications and therapeutic sessions. For these patients, a combined endoscopic approach of focal ER followed by RFA may thus be preferred over SRER. Clinical trial number NTR1337.

Entities:  

Mesh:

Year:  2011        PMID: 21209124     DOI: 10.1136/gut.2010.229310

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  86 in total

1.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

2.  Endoscopic management of high-grade dysplasia and intramucosal carcinoma: experience in a large academic medical center.

Authors:  Kyle A Perry; Jon P Walker; Mario Salazar; Andrew Suzo; Jeffrey W Hazey; W Scott Melvin
Journal:  Surg Endosc       Date:  2014-03       Impact factor: 4.584

Review 3.  Endoscopic submucosal dissection for malignant esophageal lesions.

Authors:  Hazem Hammad; Tonya Kaltenbach; Roy Soetikno
Journal:  Curr Gastroenterol Rep       Date:  2014

Review 4.  Multiband mucosectomy for advanced dysplastic lesions in the upper digestive tract.

Authors:  Jesús Espinel; Eugenia Pinedo; Vanesa Ojeda; Maria Guerra Del Rio
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

5.  Durability of radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Bergein F Overholt; Richard E Sampliner; Herbert C Wolfsen; Kenneth K Wang; David E Fleischer; Virender K Sharma; Glenn M Eisen; M Brian Fennerty; John G Hunter; Mary P Bronner; John R Goldblum; Ana E Bennett; Hiroshi Mashimo; Richard I Rothstein; Stuart R Gordon; Steven A Edmundowicz; Ryan D Madanick; Anne F Peery; V Raman Muthusamy; Kenneth J Chang; Michael B Kimmey; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; John A Dumot; Gary W Falk; Joseph A Galanko; Blair A Jobe; Robert H Hawes; Brenda J Hoffman; Prateek Sharma; Amitabh Chak; Charles J Lightdale
Journal:  Gastroenterology       Date:  2011-05-06       Impact factor: 22.682

Review 6.  Useful strategies to prevent severe stricture after endoscopic submucosal dissection for superficial esophageal neoplasm.

Authors:  Kaname Uno; Katsunori Iijima; Tomoyuki Koike; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

7.  The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study.

Authors:  Hendrik Manner; Alexander Neugebauer; Marcus Scharpf; Kirsten Braun; Andrea May; Christian Ell; Falko Fend; Markus D Enderle
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 8.  Treatment of esophagogastric junction carcinoma: an unsolved debate.

Authors:  Michele Orditura; Gennaro Galizia; Eva Lieto; Ferdinando De Vita; Fortunato Ciardiello
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium.

Authors:  Milli Gupta; Prasad G Iyer; Lori Lutzke; Emmanuel C Gorospe; Julian A Abrams; Gary W Falk; Gregory G Ginsberg; Anil K Rustgi; Charles J Lightdale; Timothy C Wang; David I Fudman; John M Poneros; Kenneth K Wang
Journal:  Gastroenterology       Date:  2013-03-15       Impact factor: 22.682

10.  Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.

Authors:  Eric S Orman; Hannah P Kim; William J Bulsiewicz; Cary C Cotton; Evan S Dellon; Melissa B Spacek; Xiaoxin Chen; Ryan D Madanick; Sarina Pasricha; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2012-12-18       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.